C6 Immunostimulants in cancer therapy
Author:
Talmadge James E.
Publisher
Birkhäuser Basel
Reference267 articles.
1. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293–9
2. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, Schellekens H, Leufkens HGM, Egberts ACG. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300: 1887–96
3. Battelle Memorial Institute. Technology Talent and Capital: State Bioscience Initiatives. 2008. 1–1–2008
4. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010; 28: 28–31
5. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148–57